• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤细胞中HDMX蛋白的异常表达与野生型p53相关。

Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53.

作者信息

Ramos Y F, Stad R, Attema J, Peltenburg L T, van der Eb A J, Jochemsen A G

机构信息

Department of Molecular Cell Biology and Center of Biomedical Genetics, Leiden University Medical Center, The Netherlands.

出版信息

Cancer Res. 2001 Mar 1;61(5):1839-42.

PMID:11280734
Abstract

It has been shown that the Hdmx gene is amplified in a subset of gliomas, but thus far, no data are available on HDMX protein expression in tumor cells. We now report that a significant fraction of tumor cell lines expresses increased HDMX levels compared with normal cells; in general, HDMX expression in these tumor cell lines correlates with the presence of wild-type p53. Analysis of tumor material showed that high HDMX expression is not a result of cell line establishment. Interestingly, several cell lines express alternative, shorter HDMX proteins. These results suggest that deregulated expression of HDMX plays a role in carcinogenesis as an alternative way to inactivate p53.

摘要

已有研究表明,Hdmx基因在部分胶质瘤中发生扩增,但到目前为止,尚无关于肿瘤细胞中HDMX蛋白表达的数据。我们现在报告,与正常细胞相比,相当一部分肿瘤细胞系中HDMX水平升高;一般来说,这些肿瘤细胞系中的HDMX表达与野生型p53的存在相关。对肿瘤材料的分析表明,HDMX的高表达不是细胞系建立的结果。有趣的是,几个细胞系表达了其他较短的HDMX蛋白。这些结果表明,HDMX的失调表达作为使p53失活的另一种方式,在致癌过程中发挥作用。

相似文献

1
Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53.肿瘤细胞中HDMX蛋白的异常表达与野生型p53相关。
Cancer Res. 2001 Mar 1;61(5):1839-42.
2
Alterations in gene expression and sensitivity to genotoxic stress following HdmX or Hdm2 knockdown in human tumor cells harboring wild-type p53.在携带野生型p53的人类肿瘤细胞中,HdmX或Hdm2基因敲低后基因表达及对基因毒性应激敏感性的改变。
Aging (Albany NY). 2009 Jan;1(1):89-108. doi: 10.18632/aging.100008.
3
Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.在人类癌症中,HDMX 抑制剂的选择性剪接比 p53 突变提供了更优越的预后生物标志物。
Cancer Res. 2012 Aug 15;72(16):4074-84. doi: 10.1158/0008-5472.CAN-12-0215. Epub 2012 Jun 14.
4
Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.HdmX蛋白的表达水平决定了正常细胞和转化细胞对Nutlin-3的敏感性。
Cancer Res. 2006 Mar 15;66(6):3169-76. doi: 10.1158/0008-5472.CAN-05-3832.
5
Differential p53, p21, mdm2 and Rb regulation in glioma cell lines that overexpress wild-type p53.过表达野生型p53的胶质瘤细胞系中p53、p21、mdm2和Rb的差异调节
Int J Oncol. 1998 Aug;13(2):213-6. doi: 10.3892/ijo.13.2.213.
6
The high levels of p53 present in adenovirus early region 1-transformed human cells do not cause up-regulation of MDM2 expression.腺病毒早期区域1转化的人细胞中存在的高水平p53不会导致MDM2表达上调。
Virology. 1995 Jul 10;210(2):323-34. doi: 10.1006/viro.1995.1349.
7
Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells.由于翻译增强导致的MDM2过表达,会致使伯基特淋巴瘤细胞中的野生型p53失活。
Oncogene. 1998 Mar 26;16(12):1603-10. doi: 10.1038/sj.onc.1201702.
8
p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3.p53在组成型激活的Stat3表达的人前列腺癌细胞中调节Stat3磷酸化和DNA结合活性。
Oncogene. 2002 May 2;21(19):3082-8. doi: 10.1038/sj.onc.1205426.
9
Selective compartmentalization of different mdm2 proteins within the nucleus.细胞核内不同MDM2蛋白的选择性区室化。
Anticancer Res. 1994 Nov-Dec;14(6B):2541-7.
10
Activation of p53 in MDM2-overexpressing cells through phosphorylation.通过磷酸化作用激活MDM2过表达细胞中的p53。
Biochem Biophys Res Commun. 1999 Nov 2;264(3):860-4. doi: 10.1006/bbrc.1999.1611.

引用本文的文献

1
Epstein-Barr virus nuclear antigen 1 (EBNA1) increases the expression levels of MDM2 and MDM4 genes in HeLa cells: a review on MDM2 and MDM4 roles in cancer.爱泼斯坦-巴尔病毒核抗原1(EBNA1)提高HeLa细胞中MDM2和MDM4基因的表达水平:MDM2和MDM4在癌症中作用的综述
BMC Res Notes. 2025 May 17;18(1):221. doi: 10.1186/s13104-025-07275-3.
2
Model-based translation of DNA damage signaling dynamics across cell types.基于模型的跨细胞类型 DNA 损伤信号转导动态翻译。
PLoS Comput Biol. 2022 Jul 8;18(7):e1010264. doi: 10.1371/journal.pcbi.1010264. eCollection 2022 Jul.
3
It's Getting Complicated-A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy.
情况愈发复杂——重新审视肿瘤发生与癌症治疗中的p53-MDM2-ARF三角关系
Front Cell Dev Biol. 2022 Jan 26;10:818744. doi: 10.3389/fcell.2022.818744. eCollection 2022.
4
MDM2-Driven Ubiquitination Rapidly Removes p53 from Its Cognate Promoters.MDM2 驱动的泛素化快速将 p53 从其同源启动子中去除。
Biomolecules. 2021 Dec 24;12(1):22. doi: 10.3390/biom12010022.
5
Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?癌症治疗中针对p53-MDM2相互作用抑制剂的耐药机制:我们能否克服它们?
Cell Mol Biol Lett. 2021 Dec 15;26(1):53. doi: 10.1186/s11658-021-00293-6.
6
Mechanisms of TP53 Pathway Inactivation in Embryonic and Somatic Cells-Relevance for Understanding (Germ Cell) Tumorigenesis.TP53 通路失活的机制在胚胎和体细胞中的作用——对(生殖细胞)肿瘤发生的理解相关。
Int J Mol Sci. 2021 May 20;22(10):5377. doi: 10.3390/ijms22105377.
7
MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma.MDM4 抑制:重新激活肝癌中 p53 的新型治疗策略。
Sci Rep. 2021 Feb 3;11(1):2967. doi: 10.1038/s41598-021-82542-4.
8
Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives.用于癌症治疗的小分子MDM2/X抑制剂和PROTAC降解剂:进展与展望
Acta Pharm Sin B. 2020 Jul;10(7):1253-1278. doi: 10.1016/j.apsb.2020.01.003. Epub 2020 Jan 14.
9
Targeting MDMX for Cancer Therapy: Rationale, Strategies, and Challenges.靶向MDMX用于癌症治疗:原理、策略与挑战
Front Oncol. 2020 Aug 5;10:1389. doi: 10.3389/fonc.2020.01389. eCollection 2020.
10
Specific allelic variants of SNPs in the and genes are associated with earlier tumor onset and progression in Caucasian breast cancer patients.某些单核苷酸多态性(SNPs)在[具体基因名称1]和[具体基因名称2]基因中的特定等位基因变体与高加索乳腺癌患者更早的肿瘤发病和进展相关。 (注:原文中两个基因名称未给出具体信息,翻译时用[具体基因名称1]和[具体基因名称2]表示)
Oncotarget. 2019 Mar 8;10(20):1975-1992. doi: 10.18632/oncotarget.26768.